Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in the Netherlands

Sabine C. de Greeff; Hester E. de Melker; Lodewijk Spanjaard; Leo M. Schouls; Arie van Derende

doi:10.1097/01.inf.0000195594.41449.c6

Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in the Netherlands

Sabine C. de Greeff
, Hester E. de Melker
, Lodewijk Spanjaard
, Leo M. Schouls
, Arie van Derende

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Routine vaccination with a single dose of conjugated meningococcal C vaccine at 14 months and a catch-up campaign have reduced the incidence of meningococcal C disease in the Netherlands. In contrast to countries where routine vaccination is given in infancy, vaccine failures were not reported. This suggests that one dose of conjugated vaccine in the second year of life might offer longer lasting protection against meningococcal C disease than 3 doses in infancy

Original language	English
Pages (from-to)	79-80
Journal	Pediatric infectious disease journal
Volume	25
Issue number	1
DOIs	https://doi.org/10.1097/01.inf.0000195594.41449.c6
Publication status	Published - 2006

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1097/01.inf.0000195594.41449.c6

Cite this

@article{ae54924ca6214b13aa2b5694de79c08c,

title = "Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in the Netherlands",

abstract = "Routine vaccination with a single dose of conjugated meningococcal C vaccine at 14 months and a catch-up campaign have reduced the incidence of meningococcal C disease in the Netherlands. In contrast to countries where routine vaccination is given in infancy, vaccine failures were not reported. This suggests that one dose of conjugated vaccine in the second year of life might offer longer lasting protection against meningococcal C disease than 3 doses in infancy",

author = "\{de Greeff\}, \{Sabine C.\} and \{de Melker\}, \{Hester E.\} and Lodewijk Spanjaard and Schouls, \{Leo M.\} and \{van Derende\}, Arie",

year = "2006",

doi = "10.1097/01.inf.0000195594.41449.c6",

language = "English",

volume = "25",

pages = "79--80",

journal = "Pediatric infectious disease journal",

issn = "0891-3668",

publisher = "Lippincott Williams and Wilkins",

number = "1",

}

TY - JOUR

T1 - Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in the Netherlands

AU - de Greeff, Sabine C.

AU - de Melker, Hester E.

AU - Spanjaard, Lodewijk

AU - Schouls, Leo M.

AU - van Derende, Arie

PY - 2006

Y1 - 2006

N2 - Routine vaccination with a single dose of conjugated meningococcal C vaccine at 14 months and a catch-up campaign have reduced the incidence of meningococcal C disease in the Netherlands. In contrast to countries where routine vaccination is given in infancy, vaccine failures were not reported. This suggests that one dose of conjugated vaccine in the second year of life might offer longer lasting protection against meningococcal C disease than 3 doses in infancy

AB - Routine vaccination with a single dose of conjugated meningococcal C vaccine at 14 months and a catch-up campaign have reduced the incidence of meningococcal C disease in the Netherlands. In contrast to countries where routine vaccination is given in infancy, vaccine failures were not reported. This suggests that one dose of conjugated vaccine in the second year of life might offer longer lasting protection against meningococcal C disease than 3 doses in infancy

U2 - 10.1097/01.inf.0000195594.41449.c6

DO - 10.1097/01.inf.0000195594.41449.c6

M3 - Article

C2 - 16395110

SN - 0891-3668

VL - 25

SP - 79

EP - 80

JO - Pediatric infectious disease journal

JF - Pediatric infectious disease journal

IS - 1

ER -

Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in the Netherlands

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this